UltraGreen.ai raises $241m led by 65 Equity and Vitruvian

Proceeds from the round will be used to support UltraGreen’s next phase of growth.

UltraGreen.ai, a surgical imaging and diagnostics company, has secured a $241m anchor investment led by 65 Equity Partners and Vitruvian Partners, with participation from August Global Partners. 

The round values the company at an equity valuation of $1.67b, according to a company announcement.

Proceeds from the round will be used to support UltraGreen’s next phase of growth and expand access to its AI-powered surgical imaging platform.

The company stated that the new investors bring strategic capabilities and international reach to its expansion plans.

Through its subsidiary Diagnostic Green, UltraGreen is currently the world’s largest provider of indocyanine green (ICG), a key imaging agent used in more than 90% of fluorescence-guided surgery (FGS) procedures globally.

The agent is marketed as IC-Green in the US and Verdye in international markets.

UltraGreen’s platform integrates ICG agents, imaging hardware, and proprietary AI-based quantification software to support the full clinical workflow—from visualisation and quantification to surgical decision-making.

The goal is to improve clinical outcomes by enhancing intraoperative assessments for surgeons.

Current clinical applications include colorectal, minimally invasive, and robotic surgeries, with a focus on perfusion assessment and anatomical visualisation. The company aims to reduce complications, shorten procedure times, and improve patient outcomes.